Compare Fabrinet (FN) vs Medpace Holdings Inc (MEDP) Price & Performance

Fabrinet (FN) trades at $571.88, up 8.5% in 24 hours, with a bearish technical signal but strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS expected at $3.81. Revenue grew to $3.42B in 2025, with a net income margin of 9.94%, though valuation ratios like P/E of 45.18 are elevated. Analyst consensus is strongly bullish with 75% buy ratings.

Outlook is positive due to AI-driven demand for optical products, but risks include high valuation and technical overbought signals. Investment opportunity hinges on continued execution in data center expansion, while investors should monitor supply chain and competitive pressures.

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.